SCHEMBL458710

SCHEMBL458710

C=CCc1ncc(N)cn1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23891952 0.77 LOXL2 (0.31)
SCHEMBL1763464 0.76 NPC1 (0.38)
SCHEMBL8994063 0.76 XDH (0.34) IMPDH2
SCHEMBL11407432 0.76 XDH (0.30)
SCHEMBL11306419 0.73 DHFR (0.42) IMPDH2
SCHEMBL175905 0.72
SCHEMBL10998624 0.71 IMPDH2 (0.35) IMPDH2
SCHEMBL29376868 0.71
SCHEMBL10824003 0.71 KDM4E (0.42)
SCHEMBL10630213 0.71 ALDH1A1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11707483-B2 Micellic assemblies UNIVERSITY OF WASHINGTON (US) 2023-07-25 US disclosed
US-20200147121-A1 MICELLIC ASSEMBLIES UNIVERSITY OF WASHINGTON (US) 2020-05-14 US disclosed
US-10420790-B2 Micellic assemblies UNIVERSITY OF WASHINGTON (US) 2019-09-24 US disclosed
US-10195284-B2 Compositions and methods for controlled localized delivery of bone forming therapeutic agents UNIVERSITY OF ROCHESTER (US) 2019-02-05 US disclosed
US-10066043-B2 ω-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization UNIVERSITY OF WASHINGTON (US) 2018-09-04 US disclosed
US-9949950-B2 Compositions and methods for controlled localized delivery of bone forming therapeutic agents UNIVERSITY OF ROCHESTER (US) 2018-04-24 US disclosed
US-20170239360-A1 MICELLIC ASSEMBLIES UNIVERSITY OF WASHINGTON (US) 2017-08-24 US disclosed
US-9662403-B2 Micellic assemblies UNIVERSITY OF WASHINGTON (US) 2017-05-30 US disclosed
US-20170145141-A1 OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION UNIVERSITY OF WASHINGTON (US) 2017-05-25 US disclosed
US-20170072062-A1 Compositions and Methods for Controlled Localized Delivery of Bone Forming Therapeutic Agents UNIVERSITY OF ROCHESTER 2017-03-16 US disclosed
WO-2009140432-A2 MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS UNIVERSITY OF WASHINGTON (US) 2009-11-19 WO disclosed
WO-2009140429-A2 MICELLIC ASSEMBLIES UNIVERSITY OF WASHINGTON (US) 2009-11-19 WO disclosed
WO-2009140423-A2 TARGETED POLYMER BIOCONJUGATES UNIVERSITY OF WASHINGTON (US) 2009-11-19 WO disclosed
WO-2009140421-A2 POLYMERIC CARRIER UNIVERSITY OF WASHINGTON (US) 2009-11-19 WO disclosed
CN-101437943-A Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease BALTIC TECHNOLOGY DEV LTD (EE) 2009-05-20 CN disclosed
EP-2013344-A2 ANTISENSE AGENTS COMBINING STRONGLY BOUND BASE - MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE Baltic Technology Development, Ltd. (EE) 2009-01-14 EP disclosed
US-20070259830-A1 Antisense Agents Combining Strongly Bound Base-Modified Oligonucleotide and Artificial Nuclease BALTIC TECHNOLOGY DEVELOPMENT (EE) 2007-11-08 US disclosed
WO-2007125173-A2 ANTISENSE AGENTS COMBINING STRONGLY BOUND BASE - MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE BALTIC TECHNOLOGY DEVELOPMENT, LTD. (EE) 2007-11-08 WO disclosed
US-5596091-A DNA AND RNA FOR GENE EXPRESSION FOR DIAGNOSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-01-21 US disclosed
US-5491264-A IMINIATION OF ISOPHORONE NITRILE USING REFRATORY OXIDE SUPPORTED HETEROPOLY ACID CATALYST TO FORM KETIMINE FOLLOWED BY REDUCTION OF KETIMINE TO ISOPHORONEDIAMINE IN PRESENCE OF HYDROGENATION CATALYST E. I. DU PONT DE NEMOURS AND COMPANY (US) 1996-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11707483-B2 Micellic assemblies UACA, CLPTM1L, BPHL IMPDH2 905/4885
US-20070259830-A1 Antisense Agents Combining Strongly Bound Base-Modified Oligonucleotide and Artificial Nuclease NCL, RNGTT, POLRMT IMPDH2 1340/4885
US-10420790-B2 Micellic assemblies UACA, CLPTM1L, BPHL IMPDH2 905/4885
US-20200147121-A1 MICELLIC ASSEMBLIES CLPX, VCL, ANXA5 IMPDH2 3261/4885
US-20170239360-A1 MICELLIC ASSEMBLIES UACA, CLPTM1L, BPHL IMPDH2 905/4885
US-10066043-B2 ω-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization FASN, ALOX5, FGB IMPDH2 4208/4885
US-20170145141-A1 OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION FASN, ALOX5, ELOVL3 IMPDH2 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.